Clinical experience with Neurox used in patients with cerebrovascular disease

Abstract

The paper presents the results of an open-label study of ethylmethylhydroxypyridine succinate (Neurox) used as a component of combination therapy in 32 patients with cerebrovascular diseases (CVD): 10 patients have experienced ischemic stroke and 22 have suffered from dyscirculatory encephalopathy. The patients with CVD have been found to have clinical improvement and better cognitive functions and to tolerate the drug well.

Keywords

• neurox
• stroke
• dyscirculatory encephalopathy